Portage Biotech Files 6-K, Updates Corporate Presentation
Ticker: ATON · Form: 6-K · Filed: Jan 18, 2024 · CIK: 1095435
| Field | Detail |
|---|---|
| Company | Portage Biotech INC. (ATON) |
| Form Type | 6-K |
| Filed Date | Jan 18, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: corporate-update, presentation, foreign-private-issuer
TL;DR
**Portage Biotech just dropped its new corporate presentation, so check it for updates on their drug pipeline.**
AI Summary
Portage Biotech Inc. filed a 6-K on January 18, 2024, primarily to furnish its latest Corporate Presentation as Exhibit 99.1. This filing indicates that the company, a foreign private issuer incorporated in the British Virgin Islands, is updating its public disclosures, which will be incorporated by reference into its existing Form F-3 (File No. 333-253468) and Form S-8 (File No. 333-275842) registration statements. For investors, this matters because the Corporate Presentation likely contains updated information on the company's drug pipeline, financial health, and strategic direction, which could influence future stock performance.
Why It Matters
This filing provides investors with the latest corporate presentation, offering insights into Portage Biotech's current operations, pipeline, and strategic outlook, which can inform investment decisions.
Risk Assessment
Risk Level: low — This 6-K filing is primarily an informational update, furnishing a corporate presentation, and does not inherently introduce new financial or operational risks.
Analyst Insight
A smart investor should review the attached Corporate Presentation (Exhibit 99.1) immediately to understand any new developments in Portage Biotech's pipeline, financials, or strategy, as this information is now publicly available and could impact future valuations.
Key Numbers
- January 18, 2024 — Filing Date (Date the 6-K report was filed and signed by Allan Shaw)
- 001-40086 — Commission File Number (Unique identifier for Portage Biotech Inc.'s filings with the SEC)
Key Players & Entities
- Portage Biotech Inc. (company) — the registrant filing the 6-K
- Allan Shaw (person) — Chief Financial Officer who signed the 6-K
- British Virgin Islands (company) — jurisdiction of incorporation for Portage Biotech Inc.
- 001-40086 (dollar_amount) — Commission File Number
- 333-253468 (dollar_amount) — File number for Form F-3 registration statement
- 333-275842 (dollar_amount) — File number for Form S-8 registration statement
Forward-Looking Statements
- The Corporate Presentation (Exhibit 99.1) will provide updated information on Portage Biotech's clinical trial progress. (Portage Biotech Inc.) — medium confidence, target: Q1 2024
- The company's stock price may see minor fluctuations based on the content of the Corporate Presentation. (Portage Biotech Inc. stock) — low confidence, target: January 2024
FAQ
What is the primary purpose of this 6-K filing by Portage Biotech Inc.?
The primary purpose of this 6-K filing is to furnish a Corporate Presentation, designated as Exhibit 99.1, to the United States Securities and Exchange Commission.
Who signed this 6-K filing on behalf of Portage Biotech Inc. and what is their title?
Allan Shaw, the Chief Financial Officer of Portage Biotech Inc., signed this 6-K filing on January 18, 2024.
Into which existing registration statements will this 6-K report be incorporated by reference?
This 6-K report will be incorporated by reference into the registration statement on Form F-3 (File No. 333-253468) and Form S-8 (File No. 333-275842) of Portage Biotech Inc.
Where are the principal executive offices of Portage Biotech Inc. located?
The principal executive offices of Portage Biotech Inc. are located at Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Islands, VG1110.
What is the Commission File Number for Portage Biotech Inc.?
The Commission File Number for Portage Biotech Inc. is 001-40086.
Filing Stats: 274 words · 1 min read · ~1 pages · Grade level 11.8 · Accepted 2024-01-18 17:09:11
Filing Documents
- f6k_011824.htm (6-K) — 14KB
- exh_991.htm (EX-99.1) — 22KB
- exh991_01.jpg (GRAPHIC) — 102KB
- exh991_02.jpg (GRAPHIC) — 296KB
- exh991_03.jpg (GRAPHIC) — 201KB
- exh991_04.jpg (GRAPHIC) — 216KB
- exh991_05.jpg (GRAPHIC) — 139KB
- exh991_06.jpg (GRAPHIC) — 133KB
- exh991_07.jpg (GRAPHIC) — 207KB
- exh991_08.jpg (GRAPHIC) — 128KB
- exh991_09.jpg (GRAPHIC) — 125KB
- exh991_10.jpg (GRAPHIC) — 166KB
- exh991_11.jpg (GRAPHIC) — 131KB
- exh991_12.jpg (GRAPHIC) — 132KB
- exh991_13.jpg (GRAPHIC) — 169KB
- exh991_14.jpg (GRAPHIC) — 119KB
- exh991_15.jpg (GRAPHIC) — 148KB
- exh991_16.jpg (GRAPHIC) — 125KB
- exh991_17.jpg (GRAPHIC) — 184KB
- 0001171843-24-000296.txt ( ) — 3786KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant’s name into English) N/A (Translation of registrant’s name into English) British Virgin Islands (Jurisdiction of incorporation or organization) Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Islands, VG1110 (Address of principal executive offices) c/o Portage Development Services Inc., Ian Walters, 203.221.7378 61 Wilton Road, Westport, Connecticut 06880 (Name, telephone, e-mail and/or facsimile number and Address of Company Contact Person) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F INCORPORATION BY REFERENCE This report on Form 6-K (including the exhibit attached hereto) shall be deemed to be incorporated by reference into the registration statement on Form F-3 (File No. 333-253468) and Form S-8 (File No. 333-275842) of Portage Biotech Inc. (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. Exhibits The following Exhibit is filed with this report: Exhibit Description 99.1 Corporate Presentation SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Portage Biotech, Inc. Date: January 18, 2024 By: /s/ Allan Shaw Name: Allan Shaw Title: Chief Financial Officer